See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

  • All
  • AAN
  • ESPID
  • APCCMI
  • ASCP
  • ASM Microbe
  • AVG and IMRP
  • CROI
  • ESCMID
  • GSA
  • IAS
  • IDWeek
  • ISIRV
  • NACFC
  • SCCM
  • All
  • 2024
  • 2025
  • 2026
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Gram-negative infection
  • Respiratory Syncytial Virus (RSV)
  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • S-337395
  • S-892216
  • Xeruborbactam
  • All
  • Oral presentation
  • Poster presentation

You Are Viewing Presentations

ESCMID 2025
Ensitrelvir

Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study  

View/Download Presentation
ESCMID 2025
Ensitrelvir

Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study

View/Download Presentation
CROI 2025
Ensitrelvir

Ensitrelvir to prevent   COVID-19 in households: SCORPIO-PEP phase III placebo-controlled trial results

View/Download Presentation
ESCMID 2026
Ensitrelvir

Ensitrelvir treatment of COVID-19 across multiple global phase 3 trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound

View/Download Presentation
IDWeek 2024
Cefiderocol

Evaluation of phenotypic cross-resistance between cefiderocol and β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers

View/Download Presentation
AAN 2026
Edaravone

Exploratory post hoc analysis of neutrophil-to-lymphocyte ratio as a novel responsiveness biomarker for edaravone oral suspension-treated patients with amyotrophic lateral sclerosis vs untreated propensity score-matched PRO-ACT historical placebo controls

View/Download Presentation

You Are Viewing Congress Locations